Citigroup Inc Pardes Biosciences, Inc. Transaction History

Citigroup Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 10, 2023	BUY	$1.4 - $1.95 $96 - $134	69 Added 130.19%	122 $0
Q1 2023 May 11, 2023	SELL	$1.21 - $2.22 $215 - $395	-178 Reduced 77.06%	53 $0
Q4 2022 Feb 09, 2023	SELL	$0.85 - $1.69 $246 - $490	-290 Reduced 55.66%	231 $0
Q3 2022 Nov 10, 2022	SELL	$2.14 - $3.7 $2,698 - $4,665	-1,261 Reduced 70.76%	521 $1,000
Q2 2022 Aug 10, 2022	SELL	$2.84 - $8.57 $2,979 - $8,989	-1,049 Reduced 37.05%	1,782 $5,000
Q1 2022 May 12, 2022	BUY	$5.64 - $15.64 $15,966 - $44,276	2,831 New	2,831 $20,000

5.23M

Ticker PRDS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,320,900
Description
Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome ...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.